专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明专利

JP2004167265A Injectable polysaccharide-cell composition 有权
公开(公告)号：JP2004167265A
公开(公告)日：2004-06-17
申请号：JP2003431538
申请日：2003-12-25
申请人： Childrens Medical Center Corp:The , Massachusetts Inst Of Technol , チルドレンズメディカルセンターコーポレイションChildren’S Medical Center Corporation , マサチューセッツインスティテュートオブテクノロジーMassachusetts Institute of Technology
发明人： GRIFFITH-CIMA LINDA , ATALA ANTHONY , VACANTI CHARLES A , PAIGE KEITH T
IPC分类号： C12N5/06 , A61F2/02 , A61K9/66 , A61K35/12 , A61K47/30 , A61L27/00 , C12N5/00
CPC分类号： A61L27/38 , A61L27/20 , A61L27/50 , C08L5/08
摘要： PROBLEM TO BE SOLVED: To obtain injectable polysaccharide which promotes engraftment, in particular, contributes to construction of muscle and cartilage tissue, and repairs defects such as reflux and incontinence. SOLUTION: A method includes a process of combining a biodegradable biocompatible hydrogel solution with isolated cells and a process of implanting the combined solution into an animal when a tissue is implanted into the animal. COPYRIGHT: (C)2004,JPO

12. 发明专利

JPH10263070A IMPLANTATION METHOD FOR LARGE CAPACITY CELL ON POLYMERIZATION MATRIX 失效
公开(公告)号：JPH10263070A
公开(公告)日：1998-10-06
申请号：JP6912398
申请日：1998-03-18
申请人： CHILDRENS MEDICAL CENTER , MASSACHUSETTS INST TECHNOLOGY
发明人： VACANTI JOSEPH P , LANGER ROBERT S , JOHNSON LYNT , GRIFFITH-CIMA LINDA
IPC分类号： C12N11/08 , A61F2/02 , A61L27/00 , A61L27/38 , C12N5/00 , C12N5/071
摘要： PROBLEM TO BE SOLVED: To implant large-capacity cell by implanting viable cell in a matrix at the time of implantation or before the implantation, and using biocompatible material having a clearance space of a specified range for enabling exchange of ingesta and gas from a blood vessel as this matrix. SOLUTION: In cell implantation of surgical operation, first a matric which can be implanted on a layer of texture is selected, and one or more matric structure are implanted between creases of the texture in such a manner as to form the layer structutre. The matrix sheet structure used in here is a porous or fibrous biocompatible material having viable parenchy cell adhering in a clearance space ranging from 100 to 200 μm, on the matrix and in the matrix, and the thickness of the matrix structure is set ranging from 200 μm to 2 mm. As such matrix sheet structure material, cited are poly-lactic acid, polyglycol acid, polyortho ester, polyanhydride, collagen and so on.

13. 发明专利

JP2013248536A Augmentation of organ function 审中-公开
标题翻译：有机功能的完成
公开(公告)号：JP2013248536A
公开(公告)日：2013-12-12
申请号：JP2013191823
申请日：2013-09-17
申请人： Childrens Medical Center Corp , チルドレンズメディカルセンターコーポレーション
发明人： ATALA ANTHONY
IPC分类号： A61L27/00 , C12M3/00 , A61K35/12 , A61L27/38 , C12N5/00 , C12N5/071
CPC分类号： C12N5/0068 , A61F2/022 , A61K35/12 , A61L27/3641 , A61L27/3683 , A61L27/3839 , A61L27/3886 , A61L2430/26 , C12N5/0685 , C12N5/0686 , C12N2501/11 , C12N2502/28 , C12N2503/04 , C12N2533/52 , C12N2533/54 , C12N2533/90
摘要： PROBLEM TO BE SOLVED: To solve a problem that there is a demand for a good method and composition for augmentation of organ functions by a manner without requiring growth or replacement of the whole organ because there are many situations in which the whole organ is not necessarily be replaced when only a part of the organ is damaged.SOLUTION: An implant material is provided wherein the implant material includes small-scale matrix material and kidney cells and is for augmentation of a natural kidney. The kidney cells are attached to the small-scale matrix material and the implant material is transplanted to the natural kidney of a human.
摘要翻译：要解决的问题：为了解决通过不需要增长或更换整个器官的方式来增加器官功能的良好方法和组成的需求的问题，因为整个器官不一定是许多情况当器官的一部分损坏时被替换。解决方案：提供植入物材料，其中植入材料包括小尺寸基质材料和肾细胞，并用于增加天然肾脏。将肾细胞连接到小规模的基质材料上，将植入材料移植到人的天然肾上。

14. 发明专利

JP2010159275A Central airway administration for systemic delivery of curative agent 审中-公开
标题翻译：中央航空公司管理系统的交付使用
公开(公告)号：JP2010159275A
公开(公告)日：2010-07-22
申请号：JP2010045407
申请日：2010-03-02
申请人： Brandeis Univ , Brigham & Womens Hospital Inc , Childrens Medical Center Corp , Syntonix Pharmaceuticals Inc , ザ・チルドレンズ・メディカル・センター・コーポレーション , ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド , シントニックス・ファーマシューティカルズ・インコーポレーテッド , ブランディーズ・ユニバーシティ
发明人： BLUMBERG RICHARD S , LENCER WAYNE I , SIMISTER NEIL E , BITONTI ALAN J
IPC分类号： A61K9/72 , A61K9/00 , A61K9/10 , A61K9/12 , A61K31/7088 , A61K38/00 , A61K38/21 , A61K38/24 , A61K38/27 , A61K39/00 , A61K39/395 , A61K45/00 , A61K47/42 , A61K47/48 , A61K48/00 , A61P5/10 , A61P5/30 , A61P7/06 , A61P15/08 , A61P31/12 , A61P35/00 , A61P43/00
CPC分类号： A61K9/0073 , A61K9/0078 , A61K47/6849
摘要： PROBLEM TO BE SOLVED: To provide a method and a product for transepithelial systemic delivery of a curative agent. SOLUTION: The method and a composition for the systemic delivery of a curative agent by administering an aerosol containing conjugates of the curative agent with an FcRn binding partner to the epithelium of central airways of the lung is provided. The method and a product (the composition) are adaptable to a wide range of curative agents, including proteins and polypeptides, nucleic acids, drugs, and others. In addition, the method and product have the advantage of not requiring administration to the deep lung in order to effect systemic delivery. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供治疗剂的跨上皮系统递送的方法和产品。提供了通过将含有治疗剂缀合物的气雾剂与FcRn结合配偶体一起给予肺部中央气道上皮的全身递送治疗剂的方法和组合物。该方法和产品（组合物）适用于广泛的治疗剂，包括蛋白质和多肽，核酸，药物等。此外，该方法和产品具有不需要施用于深肺以实现全身递送的优点。版权所有（C）2010，JPO＆INPIT

15. 发明专利

JP2009221206A Nitrosylation for deactivating apoptotic enzyme 审中-公开
标题翻译：用于抑制人体酶的NITROSYLATION
公开(公告)号：JP2009221206A
公开(公告)日：2009-10-01
申请号：JP2009111141
申请日：2009-04-30
申请人： Childrens Medical Center Corp , ザ・チルドレンズ・メディカル・センター・コーポレーション
发明人： LIPTON STUART A , TROY CAROL M
IPC分类号： A61K38/00 , A61K45/00 , A61K9/127 , A61K31/04 , A61K31/122 , A61K31/34 , A61K31/353 , A61K31/401 , A61K31/455 , A61K38/06 , A61K38/38 , A61K38/43 , A61K38/48 , A61K38/49 , A61K38/55 , A61P1/00 , A61P1/16 , A61P3/00 , A61P3/02 , A61P7/00 , A61P7/06 , A61P9/10 , A61P13/12 , A61P21/02 , A61P25/00 , A61P25/04 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/28 , A61P25/30 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00 , A61P37/00 , A61P37/02 , A61P39/02 , A61P43/00 , C12N9/99
CPC分类号： A61K9/0048 , A61K9/127 , A61K31/04 , A61K31/122 , A61K31/34 , A61K31/353 , A61K31/401 , A61K31/455 , A61K38/063 , A61K38/08 , A61K38/385 , A61K38/4873 , A61K38/488 , A61K38/49 , A61K38/556
摘要： PROBLEM TO BE SOLVED: To provide therapeutic agents for chronic neurological degenerative diseases such as amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's Disease and AIDS dementia complex caused by apoptosis as programmed cell death resulted from tissue damages due to deficiency of growth factors and exposure to active oxygen species, as well as acute focal cerebral infarction and spinal cord damage, or central nervous system trauma in other forms.
SOLUTION: Provided are therapeutic compositions containing a pseudo-caspase enzyme, and a method of ameliorating apoptotic non-neurological and non-ophthalmological cell death or damage in mammals by administrating to the mammals an effective amount of an S-nitrosylation compound.
COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供慢性神经退行性疾病如肌萎缩性侧索硬化症，亨廷顿舞蹈病，阿尔茨海默氏病和艾滋病痴呆复合物治疗剂，由细胞凋亡引起的程序性细胞死亡是由于生长因子缺乏导致的组织损伤，暴露于活性氧物质，以及急性局灶性脑梗死和脊髓损伤，或其他形式的中枢神经系统创伤。提供含有伪胱天蛋白酶的治疗组合物，以及通过向哺乳动物施用有效量的S-亚硝基化化合物来改善哺乳动物的凋亡性非神经和非眼科细胞死亡或损伤的方法。版权所有（C）2010，JPO＆INPIT

16. 发明专利

JP2009198512A Non-invasive enzyme screen for tissue remodeling-associated conditions 审中-公开
标题翻译：用于组织重组相关条件的非入侵性酶屏
公开(公告)号：JP2009198512A
公开(公告)日：2009-09-03
申请号：JP2009112427
申请日：2009-05-07
申请人： Childrens Medical Center Corp , チルドレンズメディカルセンターコーポレーション
发明人： MOSES MARSHA A , LI YAN
IPC分类号： G01N27/447 , G01N33/493 , C12Q1/00 , C12Q1/25 , C12Q1/37 , G01N33/573 , G01N33/574
CPC分类号： G01N33/573 , C12Q1/37 , G01N33/574 , G01N33/57434 , G01N33/57488 , G01N2333/96486 , G01N2333/96494 , G01N2333/99 , G01N2550/00
摘要： PROBLEM TO BE SOLVED: To characterize the molecular identity of hMW MMPs found in biological samples of subjects diagnosed with tissue remodeling-associated diseases, e.g., cancer and to provide early diagnosis/prognosis of such diseases. SOLUTION: A method and a kit are provided for detecting biological markers, e.g., high molecular-weight enzyme complexes, to non-invasively monitor the diagnosis and prognosis of tissue remodeling-associated conditions, e.g., cancers. The tissue remodeling-associated conditions encompassed by such a method include diseases such as prostate cancer, breast cancer, ovarian cancer, brain tumors, arthritic conditions, obstructive conditions, and ulcerative conditions. The method uses biological fluid samples, e.g., urine samples, that can be obtained by personnel without medical training, and does not require visiting a clinic or a hospital. The statistical association between positive results and occurrence of tissue remodeling-associated conditions is applied to the early diagnoses of the appearance of these conditions, and to prognoses changes for these conditions. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：表征在诊断患有组织重塑相关疾病（例如癌症）的受试者的生物样品中发现的hMW MMP的分子特征，并提供这种疾病的早期诊断/预后。解决方案：提供了用于检测生物标志物例如高分子量酶复合物的方法和试剂盒以非侵入性地监测组织重塑相关病症例如癌症的诊断和预后。这种方法包括的组织重塑相关病症包括诸如前列腺癌，乳腺癌，卵巢癌，脑肿瘤，关节炎病症，阻塞性病症和溃疡性病症的疾病。该方法使用生物流体样品，例如尿液样品，其可以由没有医疗培训的人员获得，并且不需要访问诊所或医院。将阳性结果与组织重建相关条件的发生之间的统计学关联应用于早期诊断这些病症的出现，并预测这些病情的变化。版权所有（C）2009，JPO＆INPIT

17. 发明专利

JP2009017887A Method for screening peptide display library by using minicell display 审中-公开
标题翻译：通过使用MINICELL显示来筛选肽显示库的方法
公开(公告)号：JP2009017887A
公开(公告)日：2009-01-29
申请号：JP2008243424
申请日：2008-09-22
申请人： Childrens Medical Center Corp , チルドレンズメディカルセンターコーポレーション
发明人： ASHKAR SAMY
IPC分类号： C12N15/09 , C12N1/20 , C12N1/21 , C12N15/10 , C12Q1/02 , C12Q1/68 , C40B40/02 , G01N33/53 , G01N33/566
CPC分类号： C40B40/02 , C07K2319/02 , C12N15/1037
摘要： PROBLEM TO BE SOLVED: To provide a method of minicell display, having a significant advantageous point in screening a peptide library for a candidate of bonding and effectively adjusting a specific biological process. SOLUTION: This method is based on the small anuclear minicell for increasing diversity in preparing unique sequences to be screened and also increasing the size of the peptides to be screened. An in vitro mutagenesis (in the level of protein synthesis) and a DNA replication increase the diversity of the libraries to be screened and therefore, substantially increase the number of potential peptides adjustable a specific biological response or mechanism. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：要解决的问题：提供一种小细胞显示的方法，在筛选候选粘合的候选者的肽文库和有效调整特定生物过程方面具有显着的优点。解决方案：该方法基于小核小细胞，用于增加准备要筛选的独特序列的多样性，并且还增加待筛选的肽的大小。体外诱变（蛋白质合成水平）和DNA复制增加了要筛选的文库的多样性，因此大大增加了可调节特定生物反应或机制的潜在肽的数量。版权所有（C）2009，JPO＆INPIT

18. 发明专利

JP2005218451A Method for screening peptide display library using minicell display 审中-公开
标题翻译：使用MINICELL显示筛选肽显示库的方法
公开(公告)号：JP2005218451A
公开(公告)日：2005-08-18
申请号：JP2005059665
申请日：2005-03-03
申请人： Childrens Medical Center Corp , チルドレンズメディカルセンターコーポレーション
发明人： ASHKAR SAMY
IPC分类号： C12N15/09 , C12N1/20 , C12N1/21 , C12N15/10 , C12Q1/02 , C12Q1/68 , C40B40/02 , G01N33/566
CPC分类号： C40B40/02 , C07K2319/02 , C12N15/1037
摘要： PROBLEM TO BE SOLVED: To provide a minicell display method which has significant advantages for screening peptide libraries for candidates that can bind and effectively modulate a particular biological process. SOLUTION: The method, based on the small and anucleate minicell, increases versatility in generating unique sequences to be screened and increases the size of the peptides to be screened. In vitro mutagenesis, at the level of protein synthesis, as well as DNA replication, increases versatility of the library to be screened and therefore substantially increases the number of potential peptides that can modulate a particular biological response or mechanism. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译：要解决的问题：提供一种小细胞显示方法，其具有显着的优点，用于筛选能够结合和有效调节特定生物过程的候选物的肽文库。解决方案：基于小和无核小细胞的方法，增加产生要筛选的独特序列的多样性，并增加要筛选的肽的大小。在蛋白质合成以及DNA复制水平的体外诱变增加了待筛选文库的通用性，因此大大增加了可调节特定生物反应或机制的潜在肽的数量。版权所有（C）2005，JPO＆NCIPI

19. 发明专利

JPH06157344A PREPARATION FOR BLOCKING NEW FORMATION OF BLOOD VESSEL AND METHOD OF BLOCKING NEW FORMATION OF BLOOD VESSEL 失效
公开(公告)号：JPH06157344A
公开(公告)日：1994-06-03
申请号：JP1869293
申请日：1993-02-05
申请人： CHILDRENS MEDICAL CENTER
发明人： MOOZESU JIYUUDA FUOOKUMAN , HARORUDO BUREMU
IPC分类号： A61K31/335 , A61K31/336 , A61K31/34 , A61K31/38 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K38/21 , A61P9/00 , A61P17/00 , A61P27/02 , A61P29/00 , A61P35/00 , C07D303/16 , C07D303/18 , C07D405/12 , C07D409/12 , C07D417/12 , A61K37/66
摘要： PURPOSE: To provide a new combination of a drug capable of improving the treatment of the disease induced by neovascularization by inhibiting the neovascularization. CONSTITUTION: The neovascularization is inhibited and the disease induced by the neovascularization is treated by using fumagillin or O-substd. fumagillol deriv. and interferon in combination. The reduction of the cancer, for example, lung cancer of an animal and the suppression of the metastasis of the cancer, for example, lung cancer of the animal are attained by the combination of the fumagillin or the Osubstd. fumagillol deriv. and the interferon.

20. 发明专利

JP2020117504A 環状プロサポシンペプチドおよびその使用审中-公开
公开(公告)号：JP2020117504A
公开(公告)日：2020-08-06
申请号：JP2020029398
申请日：2020-02-25
申请人： CHILDRENS MEDICAL CENTER
发明人： RANDOLPH S WATNICK
IPC分类号： A61K38/12 , A61P1/04 , A61P9/10 , A61P17/06 , A61P19/02 , A61P27/02 , A61P29/00 , A61P35/00 , A61P43/00 , C07K7/50
摘要：【課題】本明細書で提供されるのは、環状プロサポシンペプチドならびにその組成物および使用である。【解決手段】例示の使用としては、がんの処置または炎症性疾患もしくは障害の処置における使用が挙げられる。【選択図】なし

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式